Cord serum lipidome in prediction of islet autoimmunity and type 1 diabetesShow others and affiliations
2013 (English)In: Diabetes, ISSN 0012-1797, E-ISSN 1939-327X, Vol. 62, no 9, p. 3268-3274Article in journal (Refereed) Published
Abstract [en]
Previous studies show that children who later progress to type 1 diabetes (T1D) have decreased preautoimmune concentrations of multiple phospholipids as compared with nonprogressors. It is still unclear whether these changes associate with development of β-cell autoimmunity or specifically with clinical T1D. Here, we studied umbilical cord serum lipidome in infants who later developed T1D (N = 33); infants who developed three or four (N = 31) islet autoantibodies, two (N = 31) islet autoantibodies, or one (N = 48) islet autoantibody during the follow-up; and controls (N = 143) matched for sex, HLA-DQB1 genotype, city of birth, and period of birth. The analyses of serum molecular lipids were performed using the established lipidomics platform based on ultra-performance liquid chromatography coupled to mass spectrometry. We found that T1D progressors are characterized by a distinct cord blood lipidomic profile that includes reduced major choline-containing phospholipids, including sphingomyelins and phosphatidylcholines. A molecular signature was developed comprising seven lipids that predicted high risk for progression to T1D with an odds ratio of 5.94 (95% CI, 1.07-17.50). Reduction in choline-containing phospholipids in cord blood therefore is specifically associated with progression to T1D but not with development of β-cell autoimmunity in general.
Place, publisher, year, edition, pages
American Diabetes Association , 2013. Vol. 62, no 9, p. 3268-3274
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:oru:diva-63682DOI: 10.2337/db13-0159ISI: 000323421000035PubMedID: 23630305Scopus ID: 2-s2.0-84883230213OAI: oai:DiVA.org:oru-63682DiVA, id: diva2:1169248
Funder
EU, FP7, Seventh Framework Programme, HEALTH-F2-2008-202013
Note
Funding agencies:
Academy of Finland (Centre of Excellence in Molecular Systems Immunology and Physiology Research) 250114
Juvenile Diabetes Research Foundation 36-2008-919
2017-12-222017-12-222019-03-04Bibliographically approved